年龄≤65岁与>65岁患者外科生物瓣主动脉瓣置换术的结局
PERIGON关键试验评估Avalus生物瓣膜的安全性和有效性,按年龄≤65岁与>65岁分层分析5年随访的临床和超声心动图结局。共271例(24.2%)≤65岁和847例(75.8%)>65岁,5年死亡率年轻组更低(5.3% vs 14.0%,P<.001),两组均无结构性瓣膜退化病例。
要点
- ≤65岁组5年死亡率为5.3%,>65岁组为14.0%(P<.001)。
- 两组5年均无结构性瓣膜退化病例。
- 5年时两组95%患者纽约心脏协会心功能I/II级(P=.85)。
核心结论
- Avalus生物瓣膜在≤65岁和>65岁患者中5年随访显示满意的安全性、血流动力学性能和耐久性。
研究设计与样本
- PERIGON关键试验评估Avalus生物瓣膜(美敦力)的安全性和有效性,按年龄≤65岁与>65岁分层分析5年临床和超声心动图结局。
主要发现
- 共271例(24.2%)≤65岁和847例(75.8%)>65岁;两组男性分别为217例(80.1%)和623例(73.6%)(P=.031)。
- 年轻组胸外科医师协会死亡风险评分为1.1%±0.9%,老年组为2.2%±1.4%(P<.001),年轻组基线纽约心脏协会心功能分级更好(P=.004)且合并症更少。
- 5年死亡率年轻组为5.3%,老年组为14.0%(P<.001),两组均无结构性瓣膜退化病例。
- 有效瓣口面积两组相似(P=.11),平均跨瓣压差年轻组为13.9±5.4 mm Hg,老年组为12.0±4.1 mm Hg(P<.001)。
- 多变量线性回归识别出与5年平均主动脉瓣压差相关的参数,包括基线年龄和平均主动脉瓣压差、出院时每搏输出量指数和有效瓣口面积、以及植入瓣膜尺寸。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Implantation of a bioprosthetic valve is a reasonable choice for patients aged > 65 years. For middle-aged patients there is less certainty about whether a mechanical or bioprosthetic valve is best. METHODS: The Pericardial Surgical Aortic Valve Replacement (PERIGON) Pivotal Trial is evaluating the safety and efficacy of the Avalus bioprosthesis (Medtronic). We evaluated clinical and echocardiographic outcomes through 5 years of follow-up, stratified by age ≤ 65 and >65 years. RESULTS: Two hundred seventy-one patients (24.2%) were ≤65 years old and 847 (75.8%) >65 years old. Most patients in both groups were men (217 [80.1%] vs 623 [73.6%], respectively; P = .031). Younger patients had a lower Society of Thoracic Surgeons risk of mortality (1.1% ± 0.9% vs 2.2% ± 1.4%, P < .001), better baseline New York Heart Association class (P = .004), and fewer comorbidities than older patients. At 5 years mortality was lower among younger than older patients (5.3% vs 14.0%, P < .001) and no cases of structural valve deterioration occurred in either group. Effective orifice area was similar between age groups (P = .11), and mean gradient was 13.9 ± 5.4 vs 12.0 ± 4.1 mm Hg (P < .001). Multivariable linear regression identified several parameters associated with mean aortic gradient at 5 years, including baseline age and mean aortic gradient, discharge stroke volume index and EOA, and implanted valve size. Ninety-five percent of patients were in New York Heart Association class I/II through 5 years in both age groups (P = .85). CONCLUSIONS: Findings from this analysis demonstrate satisfactory safety, hemodynamic performance, and durability of the Avalus bioprosthesis through a 5-year follow-up in patients aged ≤ 65 and >65 years.
引用
- Kiaii BB, Moront MG, Patel HJ, et al. Outcomes of Surgical Bioprosthetic Aortic Valve Replacement in Patients Aged ≤65 and >65 Years. Ann Thorac Surg. 2022. PMID: 35065064. doi:10.1016/j.athoracsur.2021.12.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。